Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus

Irons BK, Greene RS, Mazzolini TA, Edwards KL, Sleeper RB 

Clinical data suggest that thiazolidinediones--specifically, rosiglitazone and pioglitazone--may improve cardiovascular risk factors through multiple mechanisms. Low insulin sensitivity has been described as an independent risk factor for coronary artery disease and cerebrovascular disease.  (more) 

 


Irons BK, Greene RS, Mazzolini TA, Edwards KL, Sleeper RB. Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus. Pharmacotherapy. 2006;26:168-181. 

Last Modified: 2/4/2013